 Phase III randomized clinical trial of lurbinectedin PM01183doxorubicin DOX versus cyclophosphamide CTX, doxorubicin DOX and vincristine VCR CAV or topotecan as treatment in patients with small-cell lung cancer SCLC who failed one prior platinum-containing line to determine a difference in progression-free survival PFS by an Independent Review Committee IRC between lurbinectedin PM01183doxorubicin DOX and the control arm CAV or topotecan and to analyze the median overall survival OS and mid- and long-term overall survival OS at 12, 18 and 24 months. 